Table 1.

Receptor profiles for the new multi-modal antidepressants compared with commonly used SSRIs and SNRIs^{a, b}

	Drug	5-HT1A	5-HT1B	5-HT2C	5-HT3	5-HT7	SERT inhibition	NET inhibition	DAT inhibition	α1-adrenergic
SSRI	Citalopram (Airaksinen et al., 2004)						+ + +
	Fluoxetine (Porter et al., 2003;  Mondal et al., 2007)			++			+ + +	++
SNRI	Duloxetine (Fava et al., 2006)						+ + +	+ + +	+
	Venlafaxine (Herrera- Guzman et al., 2010)						+ + +	++
Multi-modal	Vilazodone (Laughren et al., 2011)	+ + +					+ + +
	Vortioxetine (Artigas et al., 1996)	+ + +	+ + +		+ + +	+ + +	+ + +			++
	Amitifadine/DOV 216,303						+ + +	+ + +	+ + +

SSRI, serotonin reuptake inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor; SERT, serotonin transporter; NET, norepinephrine transporter; DAT, dopamine transporter; +, weak affinity, + + , moderate affinity; + + +, strong affinity.

^aBased on data from Artigas et al. (1996), Porter et al. (2003), Airaksinen et al. (2004), Fava et al. (2006), Mondal et al. (2007), Herrera-Guzman et al. (2010) and Laughren et al. (2011).

^bDue to the lack of data, brexpiprazole (OPC-34712) is not presented.